Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01331902|
Recruitment Status : Unknown
Verified April 2011 by Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : April 8, 2011
Last Update Posted : April 8, 2011
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Myocardial Ischemia||Other: Maximal Hyperemia with Adenosine Followed by Nicorandil Other: Maximal Hyperemia with Nicorandil Followed by Adenosine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Crossover Assignment|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||September 2011|
|Estimated Study Completion Date :||September 2011|
|Experimental: Adenosine Followed by Nicorandil||
Other: Maximal Hyperemia with Adenosine Followed by Nicorandil
Firstly FFR was measured with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
|Experimental: Nicorandil Followed by Adenosine||
Other: Maximal Hyperemia with Nicorandil Followed by Adenosine
Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
- Fractional Flow Reserve at Maximal Hyperemia [ Time Frame: 1 day ]
- Time to Maximal Hyperemia [ Time Frame: 1 day ]
- Changes in Heart Rate [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01331902
|Contact: Ho-Jun Jang, MDemail@example.com|
|Contact: Bon-Kwan Koo, MD.PhDfirstname.lastname@example.org|
|Study Chair:||Bon-Kwon Koo, MD. PhD||Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital|